Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...

Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...